Key Drivers
- Strong liquidity
- Deep losses
- Negative equity
AIAI Summary
PROK is now best viewed as a financed, late-stage regulatory catalyst play—not a science story—because its cash runway extends to mid-2027 and the FDA-accepted eGFR slope path makes rilparencel's Q2 2027 readout the key value inflection point, but the stock remains highly exposed to one bad data miss, timeline slip, or dilution if execution falters.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Deep losses
- •Negative equity
PROK has strong near-term liquidity with minimal debt, but deep losses, negative equity, and extreme sales-based valuation make the stock fundamentally risky despite improving cash burn.
Price Behavior
Key Price Behavior Insights:
- •Mid-May selloff
- •Rebound defense
- •Range-bound trade
Over the last month, PROK has bounced off a sharp mid-May selloff but remains below resistance, leaving the setup mixed with near-term support around $1.69-$1.75 and resistance near $1.86-$1.88.
Sharp drop from $1.96 on 2026-05-06 to $1.55 on 2026-05-19 marked a clear selloff before the rebound
Sentiment & News
Key News Insights:
- •Mixed earnings
- •Revenue beat
- •Clinical progress
ProKidney's Q1 2026 results were mixed, with a slightly larger loss than last year and consensus but revenue beating estimates as it continued advancing its late-stage CKD cell therapy program.
The report is likely neutral for the stock, as the revenue beat is offset by a modest earnings miss and no major new catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings